By virtue of simultaneous inhibiting several tyrosine kinases (namely ALK, ROS1, MET, and JAK2), (R)-crizotinib combined with CDDP (or mitomycin C) induces all the molecular and functional hallmarks of ICD in a variety of human and mouse NSCLC cell lines, even if such cells lack activating mutations of ALK or ROS1. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.